What is Medigene?
Medigene is a publicly listed biotechnology firm based in Martinsried, Germany. The company specializes in developing cutting-edge immunotherapies, focusing on T cell receptor-modified T cells (TCR‑Ts) and dendritic cell (DC) vaccines. These advanced treatments are designed to address cancer in areas with high unmet medical needs, with initial product candidates currently undergoing clinical trials. The company's scientific prowess is central to its mission of advancing oncology treatments.
How much funding has Medigene raised?
Medigene has raised a total of $117.7M across 1 funding round:
Stock Offering
$117.7M
Stock Issuance/Offering (2000): $117.7M, investors not publicly disclosed
What's next for Medigene?
The recent major strategic investment signals a pivotal phase for Medigene, likely enabling the acceleration of its clinical development pipeline and the expansion of its research capabilities. This capital infusion is expected to support the progression of its TCR-Ts and DC vaccines towards market approval, reinforcing its commitment to tackling challenging cancer indications. The company's focus on novel immunotherapies positions it for significant growth and impact in the biopharmaceutical landscape.
See full Medigene company page
